EIF2AK3 and malignant colon neoplasm: To assess whether ATF6 and IRE1 are activated alongside EIF2AK3/PERK, CCT020312-treated HT29 colon cancer and MCF7 breast cancer cells were probed for markers downstream of these different signalling effectors.